Back to results
US 2009/0068221 A1Published application
Virus-like particles as vaccines for paramyxovirus
AssigneeUniversity of Massachusetts Medical School
InventorTrudy Morrison
Life of this patent
Estimating the term…
Abstract
The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
Claims33
A recombinant virus-like particle (VLP) comprising:
- a) a Newcastle disease virus matrix (M) protein,
- b) a transmembrane domain (TM) protein,
- c) a Newcastle Disease Virus cytoplasmic domain (CT) protein, and
- d) a protein of interest,
- wherein said transmembrane (TM) protein is flanked by said cytoplasmic domain (CT) protein and said protein of interest.
2 more elements
A method for producing a protein, comprising:
- a) providing an expression vector comprising, in operable combination:
- 1) a first nucleic acid sequence encoding a transmembrane domain (TM) protein,
- 2) a second nucleic acid sequence encoding Newcastle Disease Virus cytoplasmic domain (CT) protein,
- 3) a third nucleic acid sequence encoding a protein of interest, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences, and
- 4) a fourth nucleic acid sequence encoding Newcastle Disease Virus matrix (M) protein,
- b) providing a host cell, and
- c) transfecting said host cell with said vector to produce virus-like particles (VLPs) comprising said protein of interest.
4 more elements
A method for producing a protein, comprising:
- a) providing a first expression vector comprising, in operable combination:
- 1) a first nucleic acid sequence encoding a transmembrane domain (TM) protein,
- 2) a second nucleic acid sequence encoding Newcastle Disease Virus cytoplasmic domain (CT) protein, and
- 3) a third nucleic acid sequence encoding a protein of interest, wherein said first nucleic acid sequence is flanked by said second and third nucleic acid sequences,
- b) providing a second expression vector comprising a fourth nucleic acid sequence encoding Newcastle Disease Virus matrix (M) protein,
- c) providing a host cell, and
- d) transfecting said host cell with said first and second vectors to produce virus-like particles (VLPs) comprising said protein of interest.
4 more elements
Dependencies are inferred from the claim text.